The worldwide increase in obesity and diabetes has led to predictions that nonalcoholic steatohepatitis (NASH) will become the leading indication for orthotopic liver transplantation (OLT).
transplantation (OLT). (5, 6) Because NAFLD has a very high prevalence in the general population, even a relatively small proportion of patients developing end-stage liver disease will result in a significant health burden to the population. The United States has had the highest prevalence of severe obesity for several decades. (1) Consequently, it is not surprising that recent data have demonstrated that NASH is becoming an increasingly common indication for liver transplantation (LT) overall and is already the second most common indication for LT in patients with HCC in the United States. (7) (8) (9) (10) In contrast, the demand for LT for hepatitis C virus (HCV) has declined since 2015 following the introduction of safe and effective direct-acting antivirals. Consequently, current trends suggest that NASH will surpass HCV as the most common indication for LT in the United States within the next 10 years. (11, 12) The prevalence of obesity (13) and diabetes (14) in Australia and New Zealand (ANZ) are almost similar to the United States, and thus, a similar trend in the setting of LT is anticipated in the next few years. An increasing health burden related to NASH would clearly have important implications for public health strategies and resource allocation as well as direct implications for patients competing on LT waiting lists. This current study evaluates the trends in transplantation for NASH in ANZ, where the prevalence of NAFLD is similar to the United States. (15) Our specific aims were to determine the annual frequency and temporal trends in the diagnosis of NASH-related cirrhosis, among patients with chronic liver disease (CLD) with and without HCC, who were activated for transplantation and who underwent transplantation from 1994 to 2017.
Patients and Methods
A retrospective database review of the ANZ Liver Transplant Registry data was performed for all patients aged >18 years who were listed for LT between December 31, 1994 and December 31, 2017. The ANZ Liver Transplant Registry is a prospectively collected database from the 5 LT units in Australia and the single unit in New Zealand.
Only patients listed electively for primary isolated LT were included in this study. Recipient variables at the time of transplantation included age; sex; ethnicity (Caucasian, Asian, and other); weight; specific comorbidities (diabetes mellitus, hypertension, and coronary artery disease); Model for End-Stage Liver Disease score; specific laboratory variables (total bilirubin, international normalized ratio, creatinine, and albumin level), presence of HCC; and etiology of the underlying liver disease (primary and secondary transplant indication). For the purpose of the primary outcome analysis among patients with HCC, we considered the underlying liver disease based on the secondary diagnosis provided.
Follow-up data were maintained by each unit with regular clinical review of transplant recipients. The oversight committee for the ANZLTR approved the study, and waiver of consent was obtained in accordance with the National Health and Medical Research Council guidelines for use of deidentified data.
The primary outcome was the trend in annual rates of listing and transplantation for NASH-related CLD. Secondary outcomes include the trend in annual rates of listing and transplantation for NASH-related HCC.
statistical analYsis
Clinical and demographic characteristic at the time of transplantation were described as the mean and standard deviation when normally distributed and as the median (including minimum to maximum values) when not normally distributed. The Mann-Whitney U test was used to compare means between cohorts, and categorical variables were compared using the Pearson chi-square test.
For the trend analyses, the percentages of activated and transplanted patients according to the underlying etiology of CLD were calculated for each calendar year. Subsequently, 3 types of different trend analysis were performed: 
Results

cOHOrt OvervieW
From 1994 to 2017, 5016 patients were activated for a LT in ANZ LT centers; 350 patients were excluded (fulminant liver failure, retransplant, or multiorgan transplant), and 3470 underwent OLT (Fig. 1) . Over the study period, the most common underlying etiologies of liver disease in listed patients were HCV (35%), alcoholic liver disease (16%), primary sclerosing cholangitis (PSC; 9%), hepatitis B virus (HBV) infection (9%), NASH (6%), and cryptogenic cirrhosis (CC; 4%). Other etiologies (including metabolic, non-PSC cholestatic disease, and non-HCC tumors) represented the remaining 21% of the cohort. A similar distribution of etiologies of liver disease was seen in patients undergoing OLT.
trends in etiOlOgY OF liver disease in patients activated FOr lt
The annual percentage of activated patients stratified by etiology is shown in Fig. 2 . HCV-and alcohol-related liver disease were the leading indications for listing for LT in 2017 (29.5% and 16.1%, respectively). There was no significant change in the frequency of these etiologies over the study period (Table 1 ). In contrast, during the same time period, the proportion of patients listed for NASH-related liver failure increased and the proportion listed for HBV-related liver failure decreased. By 2017, NAFLD (10.9%) had surpassed HBV (7.9%) and PSC (7.6%) and had become the third most common indication for listing for LT. A specific trend periods analysis shows significant APCs for NASH between the periods 2003-2005 and 2014-2017. On the contrary, the percentage of wait-list registrants with HBV and CC demonstrated a significant decrease in the whole period analyzed according to the trend analysis. No significant changes in the percentage of activated patients were observed for the other etiologies (Table 1) . trends in lt Figure 3 and Table 2 show the annual percentage and trend analyses of patients who underwent OLT stratified by etiology from 1994 to 2017. HCV was the leading cause of LT during the study period, accounting for 30.2% of LTs. The proportion of LTs performed for HCV-related liver failure increased over the study period. The most significant APC for HCV was observed between the period from 2006 to 2012. The proportion of LTs performed for NASH also increased significantly over the study period from 0% in 1994 to 12.4% in 2017 (Table 2 ). In the period from 1994 to 2004, the percentage of patients who underwent LT for NASH increased marginally from 0% to 2.4%. In the subsequent 12-year period, the percentage of NASH patients increased from 6.8% in 2005 to 12.4% in 2017 where it was the third leading etiology of CLD. There was a significant increase in the velocity of transplantation for NASH observed between 2004 and 2006 (APC, 72.18%; P < 0.005) and also between 2009 and 2017 (APC, 11.82%; P < 0.005).
The proportion of patients transplanted for alcohol-related liver disease remained constant, whereas the proportion of patients transplanted for PSC and CC decreased during the study period.
trends in patient activatiOn and transplantatiOn FrOM 2013-2018
To explore specific changes within the last 5 years (2013-2017) during which direct-acting antiviral Between 2003 and 2017, the median age of LT registrants significantly increased from 51 to 57 years (z = 3.41, P < 0.001; ρ = 0.91, P < 0.001). Analyzing the same period, the overall median age of NASH registrants was 57 years (range, 26-73 years), but no significant change was observed (z = 0.34, P = 0.73; NOTE: All trend analyses are based on the percentage of transplanted patients for each etiology in a calendar year. *The APC is significantly different from 0 at α = 0.05. ρ = 0.23, P = 0.74). Similarly, the median age of recipients increased significantly between 2003 (52 years) and 2017 (58 years; z = 3.40, P < 0.001; ρ = 0.90, P < 0.001) in the overall cohort, but not for NASH patients (z = 1.44, P = 0.14; ρ = 0.38, P = 0.15).
Overall, male wait-list registrants (78%) and LT recipients (79%) were predominant in the cohort. No significant change in sex was observed within the whole cohort or within NASH patients over the period analyzed (z = 0.23, P = 0.81; ρ = 0.06, P = 0.82).
Caucasian was the most common ethnicity among activated (65%) and transplanted (70%) patients. Asian patients accounted for 8% and 9% of registrants and recipients, respectively. Other ethnicities (Pacific Islander, Polynesian, Aboriginal, Hispanics, and Africans) represented 27% of activated and 30% of transplanted patients, respectively. No significant change over time occurred in ethnicity in both transplant registrants (z = 1.21, P = 0.22; ρ = 0.32, P = 0.24) and recipients (z = 0.25, P = 0.82; ρ = 0.08, P = 0.72). Similarly, there was no difference over time in ethnic groups when analyzing only NAFLD patients.
listing and transplantatiOn FOr nasH and cc
In contrast to NASH, there was a reduction in both the frequency of listing and transplantation for CC during the study period. To examine for the impact of possible misclassification of NASH as CC, the phenotypic profiles of patients with NASH and CC patients at the time of transplantation were compared (Supporting Table 3 ). In contrast to CC patients, NASH recipients had a significantly higher proportion of diabetes mellitus (50% versus 16%; P < 0.001), hypertension (18% versus 7.5%; P = 0.002), and coronary artery disease (11% versus 3%; P < 0.001) as well as a higher mean body weight at the time of transplantation (93.8 versus 68.1 kg; P < 0.001) suggesting a low misclassification rate. Furthermore, when NASH and CC were combined for the trend analysis, there remained a strong and significant increase in both activated (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) and transplanted patients (1994-2017; all trend analyses, P < 0.05; Supporting Figs. 1 and 2) .
Hcc: trends in UnderlYing etiOlOgY OF cld in listed and transplanted patients
From 2004 to 2017, 894 patients with the diagnosis of HCC were listed for LT of whom 676 underwent transplantation. Of those patients transplanted for HCC, the underlying etiology of CLD was HCV in 58%, HBV in 21%, alcoholic liver disease in 9%, NASH in 8%, and cholestatic liver disease (including PSC and primary biliary cirrhosis) in 3%.
HCV was the most common underlying liver disease in patients listed for HCC throughout the study period, and the proportion actually increased from 51% in 2004 to 63.8% in 2017 (see Fig. 4 ). During the same period, the proportion of patients listed for HCC with underlying NASH increased from 4% in 2004 to 9% in 2016-2017. The proportion of HBV-related HCC among wait-list registrants decreased significantly from 33.3% in 2004 to 20% in 2017 (Fig. 4) . No significant changes were observed for cholestatic and alcohol-related HCC (Table 3) . Similar trends were seen for patients who underwent transplantation for HCC (see Fig. 5 ). HCV was the most common underlying liver disease in patients transplanted for HCC, and the proportion increased between 2004 and 2017. The most significant During the same period, the percentage of patients listed for HCC with underlying NASH increased from 4% to 13.8% becoming the third leading cause for HCC-related LT from 2015 and showing a significant increase on trend analyses specifically in the period from 2013 to 2017 (APC, 28.82%; P < 0.05; Table 4 ). The other etiologies of liver disease-related HCC in LT recipients did not change significantly during the period analyzed.
Discussion
An analysis of trends in LT provides an important insight into the current and future disease burden associated with specific CLDs. During the 24 years up to 2017, HCV has clearly been the leading indication for LT in ANZ, accounting for one-third of all adult LTs and 60% of HCC-related transplants. Alcohol-related liver disease has remained the second leading cause for transplant, consistently accounting for approximately 16% of all transplants but a less common cause of transplants related to HCC. Notably, however, the disease burden associated with NAFLD has rapidly increased over the past 2 decades. NASH is now the third most common indication for both wait-list registration and for LT in ANZ.
Several studies from the United States have demonstrated increasing proportions of transplants being performed for underlying NASH. Analysis of the Scientific Registry of Transplant Recipients and United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network databases shows significant increases in the number and proportion of NASH transplanted patients in the United States since 2001. (13, 16, 17) In 2008, NASH surpassed alcoholic liver disease to become the second leading etiology for LT in the United States, accounting for 17% of transplants by 2014. (12) Within ANZ, NASH currently only represents approximately 12% of all transplants. Similarly, a recent analysis of the Nordic Liver Transplant Registry demonstrated that NAFLD as an indication for LT increased significantly between 1994 to 2015 but only represented 6% of adult LTs between 2011 and 2015. (18) It is notable that the velocity of obesity rates increased significantly in Australia after 1995 from an average increase of 3.1% per decade to a 6.0% increase per decade. (1) Subsequently, there was a significant increase in NASH-related transplantation 1 decade later (Table 2) , demonstrating the longterm sequelae of obesity-related liver disease. Additionally, the epidemic of obesity, which underpins the development of NAFLD, occurred in Australia a decade later than the United States, (1) suggesting that rates of end-stage liver disease and HCC related to NASH in Australia will continue to increase to mirror the experience in the United States. Given the development of cirrhosis due to NASH typically occurs over several decades, (19) it is also likely that the impact of NASH on demand for LT will be delayed in countries where the obesity epidemic is relatively recent. It is possible that different nationwide strategies of tackling obesity may also impact on future transplant rates for NAFLD.
In contrast to the increase in transplantation for NASH, other etiologies of cirrhosis are reducing in frequency. The introduction of safe and effective direct-acting antiviral therapy for HCV has reduced the number of patients listed for LT by more than one-third since 2015 in North America (9, 20) and Europe, (21) (22) (23) (24) (25) and the same reduction is likely to occur in ANZ within the next few years. Meanwhile, the number of LTs for HBV has decreased steadily thanks to universal neonatal vaccination and widespread access to safe and effective oral antiviral therapy for patients with chronic HBV. (26, 27) A similar reduction in HBVrelated activation and transplants was observed in ANZ.
A recent trend analysis of the most common causes of CLD among LT candidates with HCC in the United States showed a significant increase in the proportion of NAFLD patients from 2002 to 2016 with NAFLD representing the fastest growing indication for OLT. (10) Our analysis showed that between 2015 and 2017, NASH became the third most common etiology among HCC wait-list registrants. Additional contributing factors were the significant decrease in the prevalence of HBV-related HCC in the waiting list and the stable trend of alcohol-related HCC.
It is possible that the lack of recognition of NASH as an etiology in the first decade of the study led to a potential misclassification of NASH cirrhosis as CC. Contrasting trends in LT for NASH and CC have also been found in the UNOS database where Original article | 33 the percentage of patients with NASH cirrhosis as an indication for OLT increased from 1% to 16% between 1994 to 2016, whereas CC fell from 15% to 4%. (28, 29) In this cohort, NASH patients were more likely to have diabetes and be obese than CC patients. Similarly, in the ANZ cohort, the metabolic characteristics of NASH patients were different compared with those with CC, being older with a significantly greater body weight and prevalence of cardio-metabolic comorbidities (diabetes, hypertension, and coronary artery disease), suggesting that misclassification was minimal. In addition, when cryptogenic and NASH patients were combined, the increase in trend for transplantation remained strong, suggesting a true increase in transplantation requirements for NASH.
Our findings have important implications for the ongoing and future policy in the LT settings. With NASH likely to continue to increase as an etiology of liver disease requiring transplantation, early recognition of NASH in primary care clinics and identification of high-risk patients with subsequent tailored management are mandatory in order to decrease the proportion of patients progressing to end-stage liver disease and HCC. Currently, NASH-related cirrhosis is frequently missed as a diagnosis with the consequence of presenting with more advanced liver disease and HCC, thereby limiting potential curative options including transplantation. (30) In addition, with the increasing prevalence of metabolic factors (diabetes, overweight, or obesity), which have a negative impact on wait-list dropout rates (31) and survival after LT, (32) strategies to optimize weight and diabetes control and avoid sarcopenia should be prioritized in these patients within LT programs.
In conclusion, this study demonstrates that NASH is a rapidly growing indication for LT in ANZ. These data confirm the trends seen in the United States. However, they suggest that further significant increases in NASH cirrhosis in association with reduction in HCV-related cirrhosis are required before NASH will become the leading cause for transplantation. With the ongoing epidemics of diabetes and obesity, increased awareness of NASH coupled with effective lifestyle therapy and pharmacotherapeutics are required to reverse the significantly increasing requirements for LT.
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